Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 60 recruiting now later-stage tilt #46 of 28,707 conditions

Atrial Fibrillation: later-stage trial registry

60 of 204 indexed Atrial Fibrillation trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #46 of 28,707 conditions by registered trial count.

204 US clinical trials · 60 currently recruiting · #46 of 28,707 conditions by registered trial count

Atrial Fibrillation: 204 US clinical trials tracked, 60 recruiting.

Atrial Fibrillation is the subject of 204 registered US clinical trials on ClinicalTrials.gov, 60 of them currently open to new participants. 45 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 9 of these trials.

Enrollment posture brief

Registry condition atrial-fibrillation

OPEN 60 | RECR 29% | LATE 45 | EARLY 19 | RANK #46 | SPON 9

Nearest open-share peer: Addiction (29% recruiting · 17 trials)

Spinal Cord Injuries53.2%Mild Cognitive Impairment48.5%Dementia39.1%Glioblastoma39%Atrial Fibrillation (this)29%
Open-enrollment share among volume-matched conditions near Atrial Fibrillation

Atrial Fibrillation lists 60 open slots (29% of 204 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atrial Fibrillation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Atrial Fibrillation is recruiting below its size-band peers.

    60 of 204 indexed trials (29.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Atrial Fibrillation trials is spread across many organizations.

    The Cleveland Clinic accounts for 9 of 204 trials (4.4%). 109 distinct sponsors appear on at least one study for this condition label.

  3. Typical Atrial Fibrillation enrolment sits around 200 participants.

    Median target enrolment is 200 among the 203 trials that report a genuine target (sentinel values excluded). 59 of those (29.1%) plan for fewer than 100 participants.

  4. Atrial Fibrillation splits between interventional and observational designs.

    137 interventional and 67 observational studies make up this index (67.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 212Phase 326Phase 419

Open and recent trials

204 total, page 3 of 5

COMPLETED Phase 3 4,628 participants

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Sanofi

NCT00174785

COMPLETED Phase 3 2,725 participants

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Boehringer Ingelheim

NCT02164864

COMPLETED Phase 3 1,516 participants

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

Brigham and Women's Hospital

NCT00970489

COMPLETED Phase 4 1,500 participants

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Pfizer

NCT02100228

COMPLETED Phase 4 1,067 participants

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Boehringer Ingelheim

NCT01493557

COMPLETED Phase 2 673 participants

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

Sanofi

NCT00233441

COMPLETED 650 participants

Solutions for Atrial Fibrillation Edvocacy (SAFE)

American Pharmacists Association Foundation

NCT05067114

COMPLETED NA 650 participants

Withings ECG-Monitor Study

Withings

NCT05316337

COMPLETED Phase 3 629 participants

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

Sanofi

NCT00259376

COMPLETED NA 608 participants

EHR-Embedded Decision Support to Prevent Stroke in Patients With AF

University of Cincinnati

NCT04099485

COMPLETED NA 602 participants

Electrocardiogram Clinical Validation Study

Apple

NCT03492554

COMPLETED 581 participants

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

Duke University

NCT03719144

COMPLETED NA 561 participants

LEAVE Safe With DOACs

University of Massachusetts, Worcester

NCT04068727

COMPLETED NA 546 participants

Clinical Trial Comparing Devices Used for Cardioversion of Atrial Fibrillation

Inova Health Care Services

NCT05992623

COMPLETED 519 participants

Atrial Fibrillation/Flutter Outcome Risk Determination

Vanderbilt University

NCT01138644

COMPLETED Phase 3 504 participants

Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

Sanofi

NCT00489736

COMPLETED 497 participants

AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry

Cardiva Medical

NCT04538781

COMPLETED Phase 2 455 participants

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

Vanderbilt University

NCT00141778

COMPLETED 450 participants

Sensing Atrial High Rate Episodes With Implantable Cardioverter-Defibrillators Trial (The SENSE Trial)

Weill Medical College of Cornell University

NCT02186704

COMPLETED Phase 3 446 participants

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Forest Laboratories

NCT00035477

COMPLETED Phase 4 444 participants

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Corewell Health South

NCT05391893

COMPLETED Phase 3 431 participants

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

Forest Laboratories

NCT00035464

COMPLETED NA 421 participants

Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

Medtronic Cardiac Ablation Solutions

NCT04198701

COMPLETED NA 400 participants

Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation

Texas Cardiac Arrhythmia Research Foundation

NCT01660100

COMPLETED NA 373 participants

WIBOFA - Validation of SCT02 With ECG-App for Detection of AF

Withings

NCT06351761

COMPLETED Phase 3 356 participants

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Advanz Pharma

NCT00468767

COMPLETED NA 344 participants

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Brigham and Women's Hospital

NCT00401414

COMPLETED 339 participants

DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation

University of Utah

NCT01150214

COMPLETED NA 317 participants

Influence of Sleep Apnea on Risk of Atrial Fibrillation

The Cleveland Clinic

NCT02576587

COMPLETED Phase 3 304 participants

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

MaineHealth

NCT00953212

COMPLETED Phase 3 276 participants

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Astellas Pharma

NCT00115791

COMPLETED 271 participants

Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity

Abbott RDx Cardiometabolic

NCT01037270

COMPLETED NA 264 participants

iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology

Columbia University

NCT02731326

COMPLETED Phase 4 260 participants

Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery

Chirag Sandesara

NCT00446966

COMPLETED NA 256 participants

Video-based Detection of Atrial Fibrillation

University of Rochester

NCT04267133

COMPLETED Phase 3 253 participants

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Janssen Scientific Affairs

NCT01729871

COMPLETED 251 participants

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

Duke University

NCT02461602

COMPLETED 245 participants

Atrial Fibrillation Screening in Nursing Homes

State University of New York at Buffalo

NCT03860246

COMPLETED NA 225 participants

STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

NCT03118518

COMPLETED Phase 2 221 participants

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Advanz Pharma

NCT00267930

COMPLETED 220 participants

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

Boehringer Ingelheim

NCT02022020

COMPLETED 219 participants

QT Variability Pre and Post Cardioversion

Vanderbilt University

NCT00885391

COMPLETED 200 participants

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

University of Puerto Ri

NCT02345356

COMPLETED Phase 4 190 participants

Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation

Vanderbilt University

NCT00552084

COMPLETED NA 186 participants

STOP Persistent AF

Medtronic Cardiac Ablation Solutions

NCT03012841

COMPLETED Phase 3 176 participants

Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation

Texas Cardiac Arrhythmia Research Foundation

NCT01173809

COMPLETED 175 participants

Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation

University of Oklahoma

NCT00584922

COMPLETED NA 174 participants

Safety and Efficacy of CryoCor™ Cryoablation for PAF

Boston Scientific Corporation

NCT00231296

COMPLETED Phase 3 173 participants

Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine

Texas Cardiac Arrhythmia Research Foundation

NCT01391091

COMPLETED 160 participants

Study Watch Atrial Fibrillation (AF) Detection Investigation

Verily Life Sciences

NCT04074434

← Previous Page 3 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 12
Phase 3 26
Phase 4 19

Named interventions

Most-linked intervention names on Atrial Fibrillation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
13 trials
placebo Drug
5 trials
Apixaban Drug
4 trials
Rivaroxaban (Xarelto, BAY59-7939) Drug
3 trials
AliveCor Device
2 trials
amiodarone Drug
2 trials
Azimilide Dihydrochloride Drug
2 trials
dronedarone (SR33589) Drug
2 trials

US sites by state

Facility locations filed on Atrial Fibrillation trials. A trial with sites in several states counts in each.

California 47 trials
Florida 45 trials
New York 34 trials
Ohio 32 trials
Arizona 28 trials
Massachusetts 27 trials
Texas 26 trials
Illinois 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Atrial Fibrillation page

204 registered trials, 60 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atrial Fibrillation condition card totals 204 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.